Human epidermal growth factor receptor 2 (HER-2)–directed therapies such as trastuzumab and trastuzumab deruxtecan have improved overall survival (OS) outcomes in HER-2–positive GC [6, 7]. This evidence concerns the gene ERBB2 and gastric cancer.